Since its inception, the use of medical affairs expertise has significantly increased. The experts largely consist of medical science liaisons (MSLs) who liaise with KOLs as their unbiased, scientific partners. They also help pharma companies understand the unmet needs of these stakeholders, thereby enabling refinement of strategies. According to the benchmarks developed by the ZS […]
